Shopping Cart 0
Cart Subtotal
USD 0

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2019

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000

Details

Influenza A Virus, H3N2 Subtype Infections-Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections-Pipeline Review, H2 2019, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape.

H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H3N2 Subtype Infections-Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 8, 10, 2, 18 and 4 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 3 and 3 molecules, respectively.

Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Introduction

Influenza A Virus, H3N2 Subtype Infections-Overview

Influenza A Virus, H3N2 Subtype Infections-Therapeutics Development

Influenza A Virus, H3N2 Subtype Infections-Therapeutics Assessment

Influenza A Virus, H3N2 Subtype Infections-Companies Involved in Therapeutics Development

Influenza A Virus, H3N2 Subtype Infections-Drug Profiles

Influenza A Virus, H3N2 Subtype Infections-Dormant Projects

Influenza A Virus, H3N2 Subtype Infections-Discontinued Products

Influenza A Virus, H3N2 Subtype Infections-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019


List Of Table

List of Tables

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by AbbVie Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Adimmune Corp, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Alla Chem LLC, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Allergy Therapeutics Plc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Aphios Corp, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Asavi Llc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by AstraZeneca Plc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by AusBio Ltd, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by BiondVax Pharmaceuticals Ltd, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by BlueWillow Biologics Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Celltrion Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Cidara Therapeutics Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Emergent BioSolutions Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by FluGen Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Inovio Pharmaceuticals Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Johnson & Johnson, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Medicago Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by NanoViricides Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by New Amsterdam Sciences Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Novavax Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by OPKO Health Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Sanofi Pasteur SA, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Serum Institute of India Ltd, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Vaccitech Ltd, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Dormant Projects, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Dormant Projects, H2 2019 (Contd..1), H2 2019

Influenza A Virus, H3N2 Subtype Infections-Discontinued Products, H2 2019

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Influenza A Virus, H3N2 Subtype Infections Therapeutic Products under Development, Key Players in Influenza A Virus, H3N2 Subtype Infections Therapeutics, Influenza A Virus, H3N2 Subtype Infections Pipeline Overview, Influenza A Virus, H3N2 Subtype Infections Pipeline, Influenza A Virus, H3N2 Subtype Infections Pipeline Assessment


Companies

AbbVie Inc

Adimmune Corp

Alla Chem LLC

Allergy Therapeutics Plc

Aphios Corp

Asavi Llc

AstraZeneca Plc

AusBio Ltd

BiondVax Pharmaceuticals Ltd

BlueWillow Biologics Inc

Celltrion Inc

Cidara Therapeutics Inc

Emergent BioSolutions Inc

FluGen Inc

Inovio Pharmaceuticals Inc

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Medicago Inc

NanoViricides Inc

New Amsterdam Sciences Inc

Novavax Inc

OPKO Health Inc

Sanofi Pasteur SA

Serum Institute of India Ltd

Vaccitech Ltd

Company Profile

Company Profile Title

Influenza A Virus, H3N2 Subtype Infections-Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections-Pipeline Review, H2 2019, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape.

H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H3N2 Subtype Infections-Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 8, 10, 2, 18 and 4 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 3 and 3 molecules, respectively.

Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Introduction

Influenza A Virus, H3N2 Subtype Infections-Overview

Influenza A Virus, H3N2 Subtype Infections-Therapeutics Development

Influenza A Virus, H3N2 Subtype Infections-Therapeutics Assessment

Influenza A Virus, H3N2 Subtype Infections-Companies Involved in Therapeutics Development

Influenza A Virus, H3N2 Subtype Infections-Drug Profiles

Influenza A Virus, H3N2 Subtype Infections-Dormant Projects

Influenza A Virus, H3N2 Subtype Infections-Discontinued Products

Influenza A Virus, H3N2 Subtype Infections-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019


List Of Table

List of Tables

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by AbbVie Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Adimmune Corp, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Alla Chem LLC, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Allergy Therapeutics Plc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Aphios Corp, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Asavi Llc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by AstraZeneca Plc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by AusBio Ltd, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by BiondVax Pharmaceuticals Ltd, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by BlueWillow Biologics Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Celltrion Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Cidara Therapeutics Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Emergent BioSolutions Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by FluGen Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Inovio Pharmaceuticals Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Johnson & Johnson, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Medicago Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by NanoViricides Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by New Amsterdam Sciences Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Novavax Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by OPKO Health Inc, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Sanofi Pasteur SA, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Serum Institute of India Ltd, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Vaccitech Ltd, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Dormant Projects, H2 2019

Influenza A Virus, H3N2 Subtype Infections-Dormant Projects, H2 2019 (Contd..1), H2 2019

Influenza A Virus, H3N2 Subtype Infections-Discontinued Products, H2 2019

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Influenza A Virus, H3N2 Subtype Infections Therapeutic Products under Development, Key Players in Influenza A Virus, H3N2 Subtype Infections Therapeutics, Influenza A Virus, H3N2 Subtype Infections Pipeline Overview, Influenza A Virus, H3N2 Subtype Infections Pipeline, Influenza A Virus, H3N2 Subtype Infections Pipeline Assessment


Companies

AbbVie Inc

Adimmune Corp

Alla Chem LLC

Allergy Therapeutics Plc

Aphios Corp

Asavi Llc

AstraZeneca Plc

AusBio Ltd

BiondVax Pharmaceuticals Ltd

BlueWillow Biologics Inc

Celltrion Inc

Cidara Therapeutics Inc

Emergent BioSolutions Inc

FluGen Inc

Inovio Pharmaceuticals Inc

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Medicago Inc

NanoViricides Inc

New Amsterdam Sciences Inc

Novavax Inc

OPKO Health Inc

Sanofi Pasteur SA

Serum Institute of India Ltd

Vaccitech Ltd